Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026

Rhea-AI Summary

Alterity Therapeutics (NASDAQ: ATHE) announced multiple May 2026 medical conference presentations on its Multiple System Atrophy (MSA) development program.

Presentations include ISMRM (May 12, Cape Town), MDSANZ (May 15-17, Sydney) and MSA Symposium (May 18, London), featuring data and a clinical update on ATH434.

News Market Reaction – ATHE

+3.32%

+3.32% Session close to close

In the May 7 session, ATHE gained 3.32%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement outlines several May 2026 conferences where Alterity will showcase ATH434 data and...

Analysis

This announcement outlines several May 2026 conferences where Alterity will showcase ATH434 data and Phase 3 planning in Multiple System Atrophy, including an oral presentation on quantitative susceptibility mapping and a clinical update session. These events build on earlier Phase 2 and FDA feedback milestones. Investors may monitor how new analyses are received, the clarity of the Phase 3 design, and any subsequent regulatory or financial disclosures tied to advancing this late-stage program.

Key Figures

ISMRM presentation date: May 12, 2026, 16:00–17:50 MDSANZ conference dates: May 15–17, 2026 MSA symposium date: May 18, 2026, 16:15–17:00 +1 more

4 metrics

ISMRM presentation date May 12, 2026, 16:00–17:50 Quantitative Susceptibility Mapping in early MSA

MDSANZ conference dates May 15–17, 2026 Poster on ATH434 randomized study in MSA

MSA symposium date May 18, 2026, 16:15–17:00 ATH434 clinical update and Phase 3 planning

Abstract number Abstract #03335 Quantitative Susceptibility Mapping ISMRM presentation

Historical Context

5 past events · Latest: Apr 30 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 30	Cash flow update	Positive	-0.4%	Q3 FY26 cash flow report and corporate update with Phase 3 planning.
Apr 27	FDA feedback	Positive	+4.8%	Positive FDA Type C feedback on ATH434 Phase 3 MSA program elements.
Apr 22	Phase 2 data	Positive	-5.7%	New ATH434 Phase 2 analyses showing slowed functional decline versus placebo.
Apr 17	Board appointment	Positive	+12.6%	Appointment of experienced biotech executive to support Phase 3 advancement.
Apr 16	Conference notice	Positive	+6.4%	Announcement of late-breaker oral presentation highlighting ATH434 signals.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent clinically and strategically positive updates on ATH434 often saw mixed price reactions, with several positive catalysts followed by both gains and selloffs.

Recent Company History

Over the past month, Alterity issued multiple updates advancing ATH434 in Multiple System Atrophy. On Apr 16, it announced a late-breaker AAN oral presentation with positive Phase 2 signals, followed by new Phase 2 analyses on Apr 22. Positive FDA Type C feedback on the Phase 3 program came on Apr 27, and a Q3 FY26 cash flow and corporate update followed on Apr 30. A board appointment on Apr 17 added commercial expertise. Today’s conference presentation schedule fits this pattern of sustained clinical and regulatory engagement.

Key Terms

multiple system atrophy, quantitative susceptibility mapping, randomized, double-blind, placebo-controlled, csf nfl, +1 more

5 terms

multiple system atrophy medical

"development program in Multiple System Atrophy (MSA) will be delivered"

A progressive neurological disorder that damages multiple areas of the nervous system, causing problems with movement, balance and involuntary functions like blood pressure and bladder control; think of it as critical wiring in the body slowly failing. Investors care because the condition defines the size and urgency of the market for treatments, influences clinical trial difficulty and regulatory risk, and can lead to high per-patient pricing but also greater development uncertainty.

quantitative susceptibility mapping medical

"Title: Quantitative Susceptibility Mapping Detects Progressive Iron Accumulation"

Quantitative susceptibility mapping is an MRI-based imaging technique that measures how different tissues distort a magnetic field, producing maps of magnetic susceptibility—think of it like showing which parts of the body act like tiny magnets. It matters to investors because it can serve as a precise biomarker in clinical research and trials, improve diagnostic imaging products, and influence the value of companies that develop MRI scanners, software or treatments tied to these measurements.

randomized, double-blind, placebo-controlled medical

"Results from a Randomized, Double-Blind, Placebo-Controlled Study of ATH434"

A "randomized, double-blind, placebo-controlled" process is a method used to test the effectiveness of a new treatment or intervention. Participants are randomly assigned to different groups, with one receiving the real treatment and the other a fake version, called a placebo. Neither the participants nor the researchers know who is receiving which, which helps ensure unbiased results. For investors, this rigorous approach increases confidence that the findings are accurate and not influenced by guesswork or bias.

csf nfl medical

"Study of ATH434 in MSA using CSF NfL as a Covariate"

CSF NfL is the level of neurofilament light chain protein measured in cerebrospinal fluid, the clear liquid that cushions the brain and spine. It rises when nerve cells are damaged, so researchers use it like a smoke alarm to detect or track neurological injury or disease. For investors, changes in CSF NfL in clinical studies can signal whether a drug is slowing nerve damage and therefore affect a therapy’s development prospects and market value.

phase 3 medical

"ATH434 Clinical Update and Phase 3 Planning"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MELBOURNE, Australia and SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that presentations related to the Company’s development program in Multiple System Atrophy (MSA) will be delivered at multiple medical conferences in May 2026.

The International Society for Magnetic Resonance in Medicine 2026 ISMRM and ISMRT Annual Meeting and Exhibition

• Title: Quantitative Susceptibility Mapping Detects Progressive Iron Accumulation in Early MSA (Abstract #03335)
• Type: Oral Presentation
• Presenter: Paula Trujillo, PhD, Research Assistant Professor, Department of Neurology, Vanderbilt University Medical Center
• Date/Time: Tuesday, May 12, 2026, 16:00-17:50 local time
• Location: Cape Town, South Africa
  

Movement Disorder Society of Australia and New Zealand (MDSANZ) Scientific Meeting

• Title: Results from a Randomized, Double-Blind, Placebo-Controlled Study of ATH434 in MSA using CSF NfL as a Covariate
• Type: Poster Presentation
• Presenter: Daniel Claassen, M.D., M.S., Professor of Neurology at Vanderbilt University Medical Center and Chief Medical Advisor for Alterity
• Conference Dates: May 15-17, 2026
• Location: Sydney, Australia
  

MSA Symposium 2026

• Title: ATH434 Clinical Update and Phase 3 Planning
• Type: Oral Presentation
• Presenter: David Stamler, M.D., CEO of Alterity Therapeutics
• Date/Time: Monday, May 18, 2026, 16.15-17.00 local time
• Location: London, UK
  

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at https://alteritytx.com.

Authorisation & Additional information
This announcement was authorized by the David Stamler, CEO of Alterity Therapeutics Limited.

Contacts:

Investors:
Elyse Shapiro
ir@alteritytx.com

Remy Bernarda
Investor Relations Advisory Solutions
ir@alteritytx.com
+1 (415) 203-6386

Media
Casey McDonald
Tiberend Strategic Advisors, Inc.
cmcdonald@tiberend.com
+1 (646) 577-8520

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

FAQ

What presentations will Alterity Therapeutics (ATHE) deliver at ISMRM 2026 on May 12?

Alterity will present an oral talk titled Quantitative Susceptibility Mapping Detects Progressive Iron Accumulation in Early MSA. According to the company, Paula Trujillo, PhD, will present on May 12, 16:00-17:50 local time in Cape Town.

What will Alterity (ATHE) present at the MDSANZ Scientific Meeting in Sydney May 15-17, 2026?

Alterity will present a poster on a randomized, double-blind, placebo-controlled ATH434 study using CSF NfL as a covariate. According to the company, Daniel Claassen, MD, will be the poster presenter during the May 15-17 conference.

When and where is Alterity's ATH434 clinical update presentation at MSA Symposium 2026?

Alterity will deliver an oral clinical update and Phase 3 planning presentation on May 18, 2026 in London. According to the company, CEO David Stamler, MD, will present from 16:15-17:00 local time.

Which Alterity presenters are listed for the May 2026 conference schedule for ATHE?

Presenters include Paula Trujillo, PhD; Daniel Claassen, MD, MS; and David Stamler, MD. According to the company, each will present specific MSA-related research at the listed May 2026 events.

Does Alterity (ATHE) disclose clinical or study data in its May 2026 conference announcements?

Yes; the schedule lists a quantitative susceptibility mapping study and an ATH434 randomized study poster plus a clinical update. According to the company, these items relate directly to its MSA development program.